Oncternal Therapeutics Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Operating Revenue	2,033	2,386	1,743	1,196	320.71
Other Revenue	9.96	13.18	2.02	-	-
Revenue	2,043	2,399	1,745	1,196	320.71
Revenue Growth (YoY)	-14.85%	37.47%	45.96%	272.83%	-
Cost of Revenue	1,213	1,486	1,015	660.49	172.39
Gross Profit	829.49	913.4	730.53	535.23	148.32
Selling, General & Admin	76.43	71.09	42.21	9.91	0.95
Other Operating Expenses	66.22	36.3	16.7	7.21	0.53
Operating Expenses	147.83	112.24	62.62	17.98	1.62
Operating Income	681.66	801.16	667.91	517.25	146.7
Interest Expense	-3.59	-5.07	-0.9	-	-0.26
Interest & Investment Income	34.32	17.76	6.49	0.61	-
Other Non Operating Income (Expenses)	1.95	-0.01	5.7	0.02	-
EBT Excluding Unusual Items	714.34	813.84	679.2	517.88	146.44
Gain (Loss) on Sale of Investments	1.22	-	-	-	-
Pretax Income	715.56	813.84	679.2	517.88	146.44
Income Tax Expense	186.71	209.16	178.08	134.51	35.42
Net Income	528.85	604.68	501.12	383.37	111.02
Net Income to Common	528.85	604.68	501.12	383.37	111.02
Net Income Growth	-12.54%	20.67%	30.71%	245.32%	-
Shares Outstanding (Basic)	20	19	19	19	19
Shares Outstanding (Diluted)	20	19	19	19	19
Shares Change (YoY)	6.64%	-	-	-	-
EPS (Basic)	25.83	31.49	26.10	19.97	5.78
EPS (Diluted)	25.83	31.49	26.10	19.97	5.78
EPS Growth	-17.98%	20.67%	30.71%	245.45%	-
Free Cash Flow	-722.26	262.12	368.25	-123.19	269.37
Free Cash Flow Per Share	-35.28	13.65	19.18	-6.42	14.03
Dividend Per Share	2.500	-	-	-	-
Gross Margin	40.61%	38.07%	41.86%	44.76%	46.25%
Operating Margin	33.37%	33.39%	38.27%	43.26%	45.74%
Profit Margin	25.89%	25.20%	28.71%	32.06%	34.62%
Free Cash Flow Margin	-35.36%	10.93%	21.10%	-10.30%	83.99%
EBITDA	686.74	805.95	671.62	518.11	146.84
EBITDA Margin	33.62%	33.59%	38.48%	43.33%	45.79%
D&A For EBITDA	5.08	4.79	3.71	0.86	0.14
EBIT	681.66	801.16	667.91	517.25	146.7
EBIT Margin	33.37%	33.39%	38.27%	43.26%	45.74%
Effective Tax Rate	26.09%	25.70%	26.22%	25.97%	24.19%
Revenue as Reported	2,080	2,418	1,757	1,196	320.71

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.